Clinical Chemistry Link to Randox Laboratories Web Site
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 47: 74-80, 2001;
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (53)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Janckila, A. J.
Right arrow Articles by Yam, L. T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Janckila, A. J.
Right arrow Articles by Yam, L. T.
Related Collections
Right arrow Proteomics and Protein Markers
Right arrow Endocrinology and Metabolism
(Clinical Chemistry. 2001;47:74-80.)
© 2001 American Association for Clinical Chemistry, Inc.

Articles

Tartrate-resistant Acid Phosphatase Isoform 5b as Serum Marker for Osteoclastic Activity

Anthony J. Janckila1,a, Karen Takahashi, Susan Z. Sun and Lung T. Yam1

1 Special Hematology Laboratory, Veterans Affairs Medical Center, Louisville, KY 40206.
a Address correspondence to this author at: Department of Veterans Affairs Medical Center, 800 Zorn Ave., Louisville, KY 40206. Fax 502-894-6191; pat.streipts{at}med.va.gov

Background: Tartrate-resistant acid phosphatase (AcP) 5b is a marker of osteoclastic activity and bone resorption. Immunoassays for serum TRAcP may lack sensitivity and specificity because of the presence of non-bone isoform 5a. The purpose of this study was to isolate the serum isoforms, quantify their disease-related expressions, and test an improved immunoassay for TRAcP 5b.

Methods: We separated TRAcP isoforms chromatographically from pooled sera of healthy, rheumatoid arthritis (RA) and endstage renal disease (ESRD) subjects. TRAcP isoforms were identified by electrophoresis and quantified by biochemical and immunochemical assays. Serum TRAcP activity in healthy, RA, and ESRD cohorts was assessed at pH 5.5 and 6.1, and compared with bone alkaline phosphatase (BAP) and N-telopeptides of type I collagen (NTx).

Results: TRAcP isoforms 5a and 5b were present in all sera; 5b was identical to osteoclastic TRAcP. In serum from healthy subjects, 5a accounted for 87% of the enzyme protein but only 55% of the activity. In RA, both isoforms were increased two- to threefold in protein, but their specific activities were subnormal. In ESRD, only 5b was abnormal, being increased fivefold in protein and threefold in activity. In RA sera, TRAcP activity did not correlate with either BAP or NTx. In ESRD sera, TRAcP activity correlated with BAP and NTx only when measured at pH 6.1.

Conclusions: All sera contained both TRAcP isoforms 5a and 5b, but only 5b was present in bone. TRAcP isoform expression was variable in different diseases. Measurement of TRAcP activity at pH 6.1 improves the specificity of immunoassay for isoform 5b.




The following articles in journals at HighWire Press have cited this article:


Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
Y.-C. Chung, C.-H. Ku, T.-Y. Chao, J.-C. Yu, M. M. Chen, and S.-H. Lee
Tartrate-resistant Acid phosphatase 5b activity is a useful bone marker for monitoring bone metastases in breast cancer patients after treatment.
Cancer Epidemiol. Biomarkers Prev., March 1, 2006; 15(3): 424 - 428.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
M. Herrmann, T. Widmann, G. Colaianni, S. Colucci, A. Zallone, and W. Herrmann
Increased Osteoclast Activity in the Presence of Increased Homocysteine Concentrations
Clin. Chem., December 1, 2005; 51(12): 2348 - 2353.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
K. Kananen, L. Volin, K. Laitinen, H. Alfthan, T. Ruutu, and M. J. Valimaki
Prevention of Bone Loss after Allogeneic Stem Cell Transplantation by Calcium, Vitamin D, and Sex Hormone Replacement with or without Pamidronate
J. Clin. Endocrinol. Metab., July 1, 2005; 90(7): 3877 - 3885.
[Abstract] [Full Text] [PDF]

Home page
 J. Leukoc. Biol.Home page
A. J. Janckila, R. N. Parthasarathy, L. K. Parthasarathy, R. S. Seelan, Y.-C. Hsueh, J. Rissanen, S. L. Alatalo, J. M. Halleen, and L. T. Yam
Properties and expression of human tartrate-resistant acid phosphatase isoform 5a by monocyte-derived cells
J. Leukoc. Biol., February 1, 2005; 77(2): 209 - 218.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
T.-Y. Chao, J.-C. Yu, C.-H. Ku, M. M. Chen, S.-H. Lee, A. J. Janckila, and L. T. Yam
Tartrate-Resistant Acid Phosphatase 5b is a Useful Serum Marker for Extensive Bone Metastasis in Breast Cancer Patients
Clin. Cancer Res., January 15, 2005; 11(2): 544 - 550.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2001 by the American Association for Clinical Chemistry.